Sort
64,565 grants matching “drug discovery”
Inhibition Of Renal Injury
$1,059,411Robert A Star · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,058,087Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae
$1,058,081Zachary David Aron · Microbiotix, Inc · R01 · FY2020 · AI
Antidotes to Anthrax Lethal Factor Intoxication
$1,057,909Alan Thomas Johnson · Panthera Biopharma, Llc · U01 · FY2010 · AI
Chromatin Biology of the African Trypanosome
$1,057,830Erik Debler · Thomas Jefferson University · R01 · FY2025 · AI
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa
$1,057,733David Elihu Greenberg · Ut Southwestern Medical Center · R01 · FY2021 · AI
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses
$1,057,648John Peter Wikswo · Vanderbilt University · UH2 · FY2012 · TR
A Simultaneous SAXS/WAXS Detector System for Solving Biological Structures
$1,057,550Marc Allaire · State University New York Stony Brook · S10 · FY2012 · OD
A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation
$1,057,438Robert S Langer · Massachusetts Institute Of Technology · R01 · FY2020 · EB
ADDICTIONS: GENOTYPES, POLYMOPHISMS, AND FUNCTION
$1,057,197Rockefeller University · R01 · FY2001 · DA
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses
$1,057,133Cameron Robert Currie · University Of Wisconsin-Madison · U19 · FY2019 · AI
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
$1,057,068Ozgur Sahin · Loxigen, Inc. · R42 · FY2025 · CA
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets
$1,057,049Jeffrey S Glenn · Stanford University · R01 · FY2014 · AI
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes
$1,056,800Jeffrey H. Price · Vala Sciences, Inc. · R42 · FY2023 · HL
Comparative Biology of Tissue Repair, Regeneration and Aging
$1,056,682Kevin Strange · Mount Desert Island Biological Lab · P20 · FY2018 · GM
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
$1,056,522David A Stoltz · University Of Iowa · R01 · FY2018 · HL
Development of Pre-Erythrocytic Malaria Vaccines and antibodies
$1,056,433Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Development of Pre-Erythrocytic Malaria Vaccines and antibodies
$1,056,433Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Optimization of efflux avoidance and inhibition for antibiotic development
$1,056,326Helen I. Zgurskaya · University Of Oklahoma · R01 · FY2019 · AI
Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria
$1,056,231Ian Cyril Bathurst · Medicines For Malaria Venture · U01 · FY2007 · AI
Project 2 - Novel Therapeutics for Emerging Alphavirus
$1,056,208Daniel N Streblow · University Of Alabama At Birmingham · U19 · FY2019 · AI
Targeted natural product diversification to identify novel antibacterial agents
$1,055,950Erin Elizabeth Carlson · Trustees Of Indiana University · DP2 · FY2011 · OD
DNA Repair-on-a-Chip: Spatially Encoded Microwell Arrays
$1,055,923Jay George · Trevigen, Inc. · R44 · FY2013 · ES
Computational Molecular Pathology Research for Cancer Diagnostics and Biomarkers
$1,055,726Robert Simpson · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA
DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs
$1,055,681Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA